Arrowhead Pharmaceuticals Inc.

66.76-0.8900-1.32%Vol 291.77K1Y Perf 82.38%
Apr 19th, 2021 14:36 DELAYED
BID66.57 ASK66.70
Open66.49 Previous Close67.65
Pre-Market- After-Market-
 - -%  - -
Target Price
87.27 
Analyst Rating
Strong Buy 1.38
Potential %
30.72 
Finscreener Ranking
★★★★     53.43
Insiders Trans % 3/6/12 mo.
-100/-100/-94 
Value Ranking
★★★+     53.12
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     57.87
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap6.93B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
58.17 
Earnings Date
6th May 2021

Today's Price Range

65.9168.45

52W Range

30.8392.60

5 Year PE Ratio Range

-15.80106.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
8.85%
1 Month
-6.78%
3 Months
-16.21%
6 Months
37.00%
1 Year
82.38%
3 Years
887.59%
5 Years
985.87%
10 Years
925.00%

TickerPriceChg.Chg.%
ARWR66.76-0.8900-1.32
AAPL134.410.25000.19
GOOG2 300.652.89000.13
MSFT258.62-2.1200-0.81
XOM56.19-0.4700-0.83
WFC44.330.49001.12
JNJ162.600.36000.22
FB301.85-4.3300-1.41
GE13.410.02000.15
JPM153.06-0.2400-0.16
Financial StrengthValueIndustryS&P 500US Markets
12.50
12.90
0.04
0.05
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-140.70
-132.60
-10 423.10
-95.99
RevenueValueIndustryS&P 500US Markets
56.31M
0.54
68.21
261.09
Earnings HistoryEstimateReportedSurprise %
Q01 20211.00-0.20-120.00
Q04 20200.34-0.48-241.18
Q03 2020-0.07-0.13-85.71
Q02 2020-0.11-0.20-81.82
Q01 20200.04-0.03-175.00
Q04 20190.140.11-21.43
Q03 20190.340.21-38.24
Q02 20190.220.249.09
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.34312.50Positive
6/2021 QR-0.0573.68Positive
9/2021 FY-0.32-700.00Negative
9/2022 FY-0.0684.62Positive
Next Report Date6th May 2021
Estimated EPS Next Report0.34
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume291.77K
Shares Outstanding103.79M
Trades Count6.28K
Dollar Volume55.39M
Avg. Volume801.03K
Avg. Weekly Volume538.14K
Avg. Monthly Volume652.71K
Avg. Quarterly Volume784.35K

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock closed at 67.65 per share at the end of the most recent trading day (a -0.49% change compared to the prior day closing price) with a volume of 636.22K shares and market capitalization of 6.93B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Arrowhead Pharmaceuticals Inc. CEO is Christopher Anzalone.

The one-year performance of Arrowhead Pharmaceuticals Inc. stock is 82.38%, while year-to-date (YTD) performance is -11.83%. ARWR stock has a five-year performance of 985.87%. Its 52-week range is between 30.83 and 92.6, which gives ARWR stock a 52-week price range ratio of 58.17%

Arrowhead Pharmaceuticals Inc. currently has a PE ratio of -63.10, a price-to-book (PB) ratio of 14.55, a price-to-sale (PS) ratio of 115.71, a price to cashflow ratio of 23.90, a PEG ratio of 2.32, a ROA of -18.02%, a ROC of -20.72% and a ROE of -20.54%. The company’s profit margin is -95.99%, its EBITDA margin is -132.60%, and its revenue ttm is $56.31 Million , which makes it $0.54 revenue per share.

Of the last four earnings reports from Arrowhead Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.34 for the next earnings report. Arrowhead Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Arrowhead Pharmaceuticals Inc. is Strong Buy (1.38), with a target price of $87.27, which is +30.72% compared to the current price. The earnings rating for Arrowhead Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arrowhead Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arrowhead Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.76, ATR14 : 4.90, CCI20 : 86.80, Chaikin Money Flow : -0.08, MACD : -4.56, Money Flow Index : 60.46, ROC : 6.22, RSI : 46.59, STOCH (14,3) : 77.67, STOCH RSI : 0.97, UO : 50.32, Williams %R : -22.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arrowhead Pharmaceuticals Inc. in the last 12-months were: Bruce D. Given (Option Excercise at a value of $169 456), Bruce D. Given (Sold 28 916 shares of value $1 156 640 ), Christopher Anzalone (Option Excercise at a value of $837 556), Christopher Anzalone (Sold 305 000 shares of value $15 549 895 ), Curt Bradshaw (Sold 31 250 shares of value $2 158 124 ), Douglas B. Given (Sold 17 700 shares of value $1 413 424 ), James Hamilton (Sold 48 750 shares of value $3 622 520 ), James Hassard (Sold 15 625 shares of value $1 171 875 ), Kenneth Myszkowski (Option Excercise at a value of $811 934), Kenneth Myszkowski (Sold 116 334 shares of value $7 868 985 ), Marianne De Backer (Buy at a value of $31 330), Martin Javier San (Sold 19 500 shares of value $1 353 105 ), Mauro Ferrari (Sold 10 000 shares of value $480 000 ), Michael S. Perry (Sold 0 shares of value $-459 700 ), Michael S. Perry (Sold 76 000 shares of value $2 884 142 ), Patrick O'Brien (Option Excercise at a value of $469 800), Patrick O'Brien (Sold 115 000 shares of value $9 771 585 ), William D. Waddill (Sold 58 750 shares of value $2 399 160 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
7 (77.78 %)
5 (62.50 %)
Moderate Buy
1 (12.50 %)
1 (11.11 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (11.11 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (12.50 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.33
Moderate Buy
2.00

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

CEO: Christopher Anzalone

Telephone: +1 626 304-3400

Address: 177 E. Colorado Boulevard, Pasadena 91105, CA, US

Number of employees: 232

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

75%25%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

Bearish Bullish

57%43%

News

Stocktwits